Neuroendocrine tumors are rare, accounting for less than 1% of all malignant tumors, and most of them occur in the stomach, intestines, and pancreas. The most common type of cancer in this type of tumor is carcinoid, with an incidence of about 2.5/100000, accounting for 50% of all gastrointestinal pancreatic neuroendocrine tumors. Carcinoid tumors can be divided into anterior intestine (lung, lung, Bronchus and upper gastrointestinal tract up to jejunum), midgut (ileum and appendix) and hindgut (rectum and rectum). Such tumors can occur in the entire neuroendocrine system, but the most common site of involvement is the pancreas. Neuroendocrine tumors can be divided into two major categories according to whether the substances secreted by the buro cause typical clinical symptoms mdash; mdash; functional and non-functional.
Waqtigan xaadirka ah, daawaynta ugu waxtarka badan ee burooyinka neuroendocrine ee adduunka waa peptide reseptor radionuclide therapy (PRRT). Kuwa soo socda waa maqaal uu qoray dhakhtar Mareykan ah oo ku saabsan daawaynta radiyonuclide reseptor peptide:
Waa maxay peptide receptor Radionuclide therapy (PRRT)?
Waa maxay peptide receptor radionuclide therapy (PRRT) sideese u shaqeysaa?
Peptide reseptor radionuclide therapy (PRRT) waa daawayn laxidhiidha molecular (sidoo kale loo yaqaan radioisotope therapy) oo loo isticmaalo daawaynta noocyo gaar ah oo kansar ah, oo loo yaqaanno malignancies neuroendocrine ama burooyinka Neuroendocrine (burooyinka neuroendocrine). Peptide reseptor radionuclide therapy (PRRT) ayaa sidoo kale loo bartay daawaynta qanjirka 'prostate' iyo burooyinka ganaca.
Daawaynta reseptor-ka ee radionuclide (PRRT), borotiinka (ama peptide) loo yaqaan bartilmaameedka unugga ee loo yaqaan octreotide, oo ay weheliso qiyaas yar oo ah walxo shucaac ah, ama radionuclide, waxay soo saartaa nooc gaar ah oo radiopharmaceutical ah oo loo yaqaan peptide radioactive. Marka lagu duro dhiigga bukaanka, shucaacani wuxuu galaa oo ku xidhaa unugyada burooyinka neuroendocrine, taasoo siinaysa shucaac aad u sarreeya dhaawaca kansarka.
Inta badan unugyada burooyinka neuroendocrine, kobcinta (oo loo yaqaan 'overexpression') waxay leedahay tiro badan oo ah noocyada gaarka ah ee soo-dhoweynta dusha sare - borotiinkan waxaa lagu qaybiyaa dusha unugyada - hoormoonka ku xiran jirka waxaa loo yaqaan 'hormone hormone inhibitory factor'. Octreotide waa hoormoon lagu sameeyay shaybaarka, kaas oo ku dheggan neuroendocrine tumor koritaanka hormoonka inhibitory factor reseptor. Daawaynta reseptor-ka ee radionuclide therapy (PRRT), octreotide oo ay weheliso qiyaasaha daawaynta ee radionuclide yttrium-90 (Y-90) iyo luteium 177 (Lu-177) waa radionuclide-ka ugu badan ee la isticmaalo.
Waa maxay cudurrada lagu daweyn karo peptide reseptor radionuclide therapy (PRRT)?
Is peptide receptor radionuclide therapy ( PRRT) used to treat neuroendocrine tumors? (NETs), including burooyinka kansarka, pancreatic islet cell carcinoma, small cell lung cancer, pheochromocytoma (a rare tumor formed in the adrenal glands), stomach-intestine-pancreas (stomach, intestine and pancreas) neuroendocrine tumors, And rare thyroid cancer that does not respond to radioactive iodine therapy.
Daawaynta daawaynta radionuclide receptor Peptide (PRRT) waa ikhtiyaarka bukaanada:
•Bukaanku waxa uu leeyahay burooyin neuroendocrine horumarsan iyo/ama horumarsan
• Bukaannada aan ku habboonayn qalliinka
• Calaamadaha bukaanku kama jawaabaan daawooyinka kale
Hadafka ugu weyn ee daawada peptide reseptor radionuclide (PRRT) waa in lagu caawiyo nafiska calaamadaha, joojinta ama dib u dhigista horumarka burada iyo hagaajinta guud ahaan badbaadada.
Sidee buu u shaqeeyaa daawaynta radionuclide receptor peptide (PRRT)?
Iyadoo ku xiran nooca kansarka ee la daweynayo iyo qalabka daaweynta ee fulinaya habka daaweynta, bukaanku waxay heli karaan ilaa 10 wareegyo ee Peptide receptor radionuclide therapy (PRRT), oo la kala soocay 2-3 bilood gudahood. Iyada oo ku xidhan daawaynta radionuclide ee la fulinayo iyo xeerarka maxalliga ah, nidaamkan waxa loo isticmaali karaa hab daawaynta bukaan-socod, ama waxa ay u baahan kartaa dhawr maalmood oo daawaynta cusbitaal ah.
Daaweyn kasta oo loo yaqaan 'peptide receptor radionuclide therapy' (PRRT) waxay bilaabataa marka amino acids si sahal ah xididada looga duro si kelyaha bukaanka looga ilaaliyo shucaaca. peptide shucaac ah ayaa markaa kadib lagu duraa bukaanka, oo ay ku xigto xal amino acid oo dheeraad ah. Wadar ahaan, muddada daawaynta ayaa socotay ku dhawaad 4 saacadood.
Inta lagu jiro daawaynta xigta, baadhista sawirka molecular ayaa laga yaabaa in la sameeyo si loo eego halka uu jirka ka galay peptide shucaac ah oo la isku duray, inkasta oo aanay kuwani ahayn qasab.
Waa maxay faa'iidooyinka peptide reseptor radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy ( PRRT) and other molecular therapies can provide more individualized cancer treatment because radiopharmaceuticals can be adjusted according to the patient’s unique biological characteristics and the molecular characteristics of the tumor. Peptide receptor radionuclide therapy (PRRT) is also considered to be a targeted therapy, because radioactive peptides have the ability to highly selectively destroy neuroendocrine tumor cells, while limiting normal tissue exposure to radiation. Therefore, in general, peptide receptor radionuclide therapy (PRRT) has relatively mild side effects compared to chemotherapy.
Peptide receptor radionuclide therapy (PRRT) waa nooc leh heerar sare oo wax ku ool ah oo ah xulashooyinka daawaynta ee xakameynta burada neuroendocrine ee horumarsan, horumarsan. Peptide reseptor radionuclide therapy (PRRT) maaha daawaynta daawaynta, laakiin waxa la tusay in ay caawiso nafiska calaamadaha iyo dib u dhigista horumarka cudurka.
Daawaynta radionuclide reseptor (PRRT) ma badbaado baa?
Dhammaan daawaynta, oo ay ku jiraan peptide receptor radionuclide therapy (PRRT), waxay leeyihiin waxyeelo iyo khataro. Waa inaad kala hadashaa halista iyo faa'iidooyinka peptide reseptor radionuclide therapy (PRRT) bixiyahaaga daawaynta, iyo sidoo kale daawaynta kale ee aad ka fiirsanayso. Iyada oo ku saleysan taariikhdaada caafimaad, bixiyahaaga daawaynta ayaa kaa caawin doona inaad go'aansato in daawaynta radionuclide reseptor (PRRT) ay tahay doorashadaada ugu saxsan iyo in kale. Hubi inaad u sheegto bixiyahaaga daawaynta wixii ku saabsan daawayn kale oo hore oo aad qaadatay, maadaama ay tani door muhiim ah ka ciyaareyso go'aaminta saxda ah ee daaweynta iyo qiyaasta daawada.
Dhibaatooyinka soo raaca ee daawada peptide reseptor radionuclide (PRRT)?
Peptide reseptor radionuclide therapy (PRRT) lafteedu si aad u wanaagsan ayaa loo dulqaadan karaa, laakiin inta lagu jiro faleebo amino acid, bukaanku badanaa waxay leeyihiin lallabbo iyo matag (mararka qaarkood aad u daran). Tani waxay u baahan tahay daawaynta ka hortagga lalabo ama hoos u dhigidda heerka maamulka amino acid. Muddada dheer, dhibaatooyinka soo raaca waxaa ka mid noqon doona tirinta dhiigga joogtada ah. Guud ahaan, daawayntan si wanaagsan ayay bukaanada intooda badan u dulqaataan.
Daryeelka guriga
Xaruntaada caafimaad ayaa ku siin doonta hagitaan daawaynta xigta. Sababtoo ah qadar yar oo shucaac ah ayaa ku sii jiri kara jirka, bukaanadu waxay u baahan yihiin in la mariyo daaweyn kale 1-2 maalmood ka dib marka la helo daweynta peptide receptor radionuclide (PRRT). Sababtoo ah inta soo hartay radionuclides waxaa laga nadiifiyaa jirka iyada oo loo marayo kaadida iyo saxarada, waxaa muhiim ah in la ilaaliyo nadaafadda musqusha muddadan.
Waa maxay horumarka cusub ee cilmi-baarista peptide reseptor radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy (PRRT) research is now focused on completing phase III clinical trials, and hopes to receive US FDA approval for its indications shortly thereafter. Ongoing research also includes research on these applications:
• Wada isticmaal laba peptides
• peptides radioactive oo ay weheliyaan daawaynta kale ee kiimoterabiga
• Codsiga daaweynta shucaaca ee soo noqnoqda
• Increase the number of indications for this type of radiation therapy, including other disease targets
• Isticmaalka wadajirka ah ee radionuclide-peptide kale.
